Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 1,307 trials

Myasthenia Gravis: Rozanolixizumab for Kids

We are studying if rozanolixizumab is safe and effective for children with moderate to severe myasthenia gravis. This trial will help us understand how the medication works in young patients.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNeurologyPediatrics

Semaglutide for Glucose Intolerance in Women with Prior Gestational Diabetes

We are studying whether semaglutide can help women with a history of gestational diabetes manage glucose intolerance and reduce the risk of developing type 2 diabetes.

Prediabetes>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGynecology and Obstetrics

Primary IgA Nephropathy: RO7434656 Treatment Study

We are testing a new medication to see if it helps reduce protein in urine and improves kidney function in patients with Primary IgA Nephropathy at high risk of progression. The study will also evaluate safety and fatigue levels.

IgA Nephropathy>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Pancreatic Cancer: Short vs. Long Chemotherapy

We are comparing two lengths of chemotherapy before surgery for patients with borderline and locally advanced pancreatic cancer. Our goal is to find out which duration may help improve survival rates.

Advanced Pancreatic Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyOncology

Neuroendocrine Tumors: 177Lu-edotreotide vs. Everolimus

We are studying whether a new treatment, 177Lu-edotreotide, can help patients with neuroendocrine tumors of the lung and thymus live longer without disease progression compared to everolimus.

Neuroendocrine Tumor>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Hydroxychloroquine for Extra-pulmonary Sarcoidosis

We are studying whether hydroxychloroquine can reduce the need for steroids in patients with extra-pulmonary sarcoidosis. This trial will also look at its effects on quality of life and potential side effects.

Sarcoidosis>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineRheumatology

Chronic Spontaneous Urticaria: Remibrutinib for Teens

We are studying a new medication, remibrutinib, for adolescents with chronic spontaneous urticaria that isn't well controlled by antihistamines. The goal is to see if it can reduce symptoms like hives and itching more effectively than a placebo.

Chronic Spontaneous Urticaria3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Kidney Disease: Iptacopan (LNP023) Study

We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.

Idiopathic Immune Complex Mediated Membranoproliferative GlomerulonephritisConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Hypogammaglobulinemia: XEMBIFY Treatment Study

We are testing whether XEMBIFY, combined with standard treatment, can help prevent infections in patients with hypogammaglobulinemia linked to blood cancers. This study compares its effects to a placebo treatment.

Chronic Lymphocytic Leukaemia1-2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInfectious DiseasesOncology

Ventilator-Acquired Pneumonia: Interferon Gamma Treatment

We are studying whether recombinant human interferon gamma can help ICU patients with ventilator-acquired pneumonia breathe easier and recover faster. This trial looks at its effects alongside standard antibiotic treatment.

Ventilator-Associated PneumoniaConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Open Angle Glaucoma: Citicoline Eye Drops

We are studying whether citicoline eye drops can help preserve vision in patients with open angle glaucoma. The trial also looks at the safety of these drops and their effects on eye structure.

Glaucoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Focal-Onset Seizures: Study of XEN1101

We are testing a new medication, XEN1101, to see if it can help reduce the frequency of focal-onset seizures. This study compares its effects to a placebo in participants with this condition.

Focal Epilepsy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

XEN1101 for Primary Generalized Tonic-Clonic Seizures

We are studying whether XEN1101 can help reduce the frequency of seizures in people with Primary Generalized Tonic-Clonic Seizures compared to a placebo. This trial aims to understand its safety and impact on seizure control.

Generalized Tonic-Clonic SeizureConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology